Published in Mol Cancer Ther on May 01, 2006
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res (2008) 1.74
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release (2009) 1.42
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res (2008) 1.42
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol (2008) 1.04
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. Mol Pharm (2012) 1.03
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther (2012) 1.00
(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res (2010) 0.98
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol (2007) 0.96
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol (2008) 0.96
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer (2011) 0.93
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release (2012) 0.89
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol (2011) 0.89
Network analysis identifies an HSP90-central hub susceptible in ovarian cancer. Clin Cancer Res (2013) 0.88
Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells. Proc Natl Acad Sci U S A (2014) 0.87
Multi-drug delivery to tumor cells via micellar nanocarriers. Int J Pharm (2011) 0.86
Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer (2013) 0.85
Heat shock proteins in animal neoplasms and human tumours--a comparison. Cell Stress Chaperones (2008) 0.84
The Warburg effect and drug resistance. Br J Pharmacol (2016) 0.81
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer (2015) 0.80
MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Mol Pharm (2010) 0.77
Proteome interrogation using nanoprobes to identify targets of a cancer-killing molecule. J Am Chem Soc (2011) 0.77
17AAG-induced internalisation of HER2-specific Affibody molecules. Oncol Lett (2016) 0.75
Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors. Mol Pharm (2016) 0.75
Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer. J Control Release (2017) 0.75
Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A (2008) 4.75
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell (2002) 3.89
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res (2008) 2.76
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res (2006) 2.55
HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
New approaches to molecular cancer therapeutics. Nat Chem Biol (2006) 2.28
Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett (2007) 2.21
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer (2006) 2.11
A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Rep (2008) 2.09
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 2.06
A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription. Cancer Res (2010) 2.05
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J Med Chem (2010) 2.04
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle (2009) 1.96
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol (2013) 1.90
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
A public-private partnership to unlock the untargeted kinome. Nat Chem Biol (2013) 1.83
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol (2004) 1.80
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res (2005) 1.78
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77
Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle (2010) 1.75
Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res (2007) 1.71
Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem (2002) 1.70
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem (2007) 1.67
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2007) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol (2007) 1.63
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.62
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res (2011) 1.61
Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorg Med Chem Lett (2007) 1.61
Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell (2008) 1.57
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res (2013) 1.54
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2008) 1.48
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One (2009) 1.44
Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep (2005) 1.43
High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem (2004) 1.42
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene (2005) 1.41
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. Eur J Cancer (2010) 1.40
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res (2010) 1.40
HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today (2011) 1.40
A mouse model recapitulating molecular features of human mesothelioma. Cancer Res (2005) 1.39
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov (2013) 1.34
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res (2009) 1.34
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem Lett (2007) 1.33
HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest (2013) 1.32
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs (2010) 1.30
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res (2006) 1.29
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst (2003) 1.29
Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem (2006) 1.29
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res (2011) 1.27
Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells. Cytometry A (2003) 1.25
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res (2009) 1.24
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res (2005) 1.24
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today (2009) 1.24
Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res (2007) 1.24
Death by chaperone: HSP90, HSP70 or both? Cell Cycle (2009) 1.22
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther (2006) 1.21
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol (2007) 1.20
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther (2007) 1.19
Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol (2012) 1.19
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res (2004) 1.19
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res (2006) 1.19
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol (2011) 1.18
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett (2005) 1.17
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem (2009) 1.17
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther (2008) 1.16
The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets (2003) 1.16
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem (2004) 1.16
Structure-based design of molecular cancer therapeutics. Trends Biotechnol (2009) 1.16
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.15
The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15
Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther (2005) 1.15
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14
Drugging the PI3 kinome. Nat Biotechnol (2006) 1.14